Chemistry:Zorifertinib
From HandWiki
Zorifertinib (AZD3759) is a drug for the treatment of cancer.[1] In China, it was approved in 2024 for locally advanced or metastatic non-small-cell lung cancer (NSCLC) that has epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations and central nervous system (CNS) metastases.[2]
References
- ↑ "First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial". Med 6 (1). January 2025. doi:10.1016/j.medj.2024.09.002. PMID 39389055.
- ↑ "Zorifertinib Receives NMPA Approval for EGFR+ NSCLC With CNS Metastases". November 20, 2024. https://www.onclive.com/view/zorifertinib-receives-nmpa-approval-for-egfr-nsclc-with-cns-metastases.
 |  |
